OB:GENT-ME

Stock Analysis Report

Gentian Diagnostics

Executive Summary

Gentian Diagnostics AS researches, develops, and produces biochemical reagents for use in medical diagnostics and research.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Share Price & News

How has Gentian Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.1%

GENT-ME

3.0%

NO Medical Equipment

1.1%

NO Market


1 Year Return

-26.0%

GENT-ME

15.9%

NO Medical Equipment

-7.3%

NO Market

Return vs Industry: GENT-ME underperformed the Norwegian Medical Equipment industry which returned 15.9% over the past year.

Return vs Market: GENT-ME underperformed the Norwegian Market which returned -7.3% over the past year.


Shareholder returns

GENT-MEIndustryMarket
7 Day1.1%3.0%1.1%
30 Day-4.2%-1.2%-0.7%
90 Day-7.1%0.7%2.3%
1 Year-26.0%-26.0%17.8%15.9%-2.5%-7.3%
3 Yearn/a63.9%55.5%41.3%22.8%
5 Yearn/a125.1%103.8%59.8%22.9%

Price Volatility Vs. Market

How volatile is Gentian Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Gentian Diagnostics undervalued compared to its fair value and its price relative to the market?

2.96x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate GENT-ME's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate GENT-ME's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GENT-ME is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: GENT-ME is unprofitable, so we can't compare its PE Ratio to the Norwegian market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate GENT-ME's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GENT-ME is good value based on its PB Ratio (3x) compared to the XE Medical Equipment industry average (3.2x).


Next Steps

Future Growth

How is Gentian Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

19.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Gentian Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Gentian Diagnostics performed over the past 5 years?

-40.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: GENT-ME is unprofitable, and losses have increased over the past 5 years at a rate of -40.2% per year.

Accelerating Growth: Unable to compare GENT-ME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GENT-ME is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (5.5%).


Return on Equity

High ROE: GENT-ME has a negative Return on Equity (-18.82%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: GENT-ME is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: GENT-ME is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Gentian Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: GENT-ME's short term assets (NOK211.8M) exceeds its short term liabilities (NOK9.9M)

Long Term Liabilities: GENT-ME's short term assets (211.8M) exceeds its long term liabilities (4.8M)


Debt to Equity History and Analysis

Debt Level: GENT-ME's debt to equity ratio (0.3%) is considered satisfactory

Reducing Debt: GENT-ME's debt to equity ratio has reduced from 177.7% to 0.3% over the past 5 years.


Balance Sheet

Inventory Level: GENT-ME has a low level of unsold assets or inventory.

Debt Coverage by Assets: GENT-ME's debt is covered by short term assets (assets are 342.134080x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GENT-ME has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: GENT-ME has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 3.5% each year


Next Steps

Dividend

What is Gentian Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.6%markettop25%6.3%industryaverage1.4%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate GENT-ME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate GENT-ME's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if GENT-ME's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GENT-ME's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GENT-ME's dividend in 3 years as they are not forecast to pay a notable one for the Norwegian market.


Next Steps

Management

What is the CEO of Gentian Diagnostics's salary, the management and board of directors tenure and is there insider trading?


CEO

Hilja Ibert 0

1.3yrs

Tenure

0

Dr. Hilja Ibert has been the Chief Executive Officer of Gentian Diagnostics AS since July 16, 2018. Dr. Ibert has more than 25 years' experience from the international diagnostic industry, and an extensive ...


Insider Trading

Insider Buying: GENT-ME insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Buykr99,97511 Sep 19
Teakay Invest As
EntityCompany
Shares2,325
Max Pricekr43.00
Buykr1,720,00011 Sep 19
Henrik Krefting
EntityIndividual
Role
Member of the Board of Directors
Director
Shares40,000
Max Pricekr43.00
Buykr8,800,12211 Sep 19
Vatne Capital AS
EntityCompany
Shares204,654
Max Pricekr43.00
Buykr249,95911 Sep 19
Hilja Ibert
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares5,813
Max Pricekr43.00
Buykr99,97511 Sep 19
Kari Krogstad
EntityIndividual
Role
Member of the Board of Directors
Director
Shares2,325
Max Pricekr43.00
Buykr999,96511 Sep 19
Mutus AS
EntityCompany
Shares23,255
Max Pricekr43.00
Buykr999,96511 Sep 19
P53 Invest AS
EntityCompany
Shares23,255
Max Pricekr43.00
Sellkr13,399,96111 Sep 19
Erling Sundrehagen
EntityIndividual
Shares311,627
Max Pricekr43.00
Buykr430,00011 Sep 19
Njaal Kind
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares10,000
Max Pricekr43.00
Buykr560,00028 Feb 19
Njaal Kind
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares10,000
Max Pricekr56.00
Buykr9,537,50129 Jan 19
Vatne Capital AS
EntityCompany
Shares175,000
Max Pricekr54.50

Ownership Breakdown


Management Team

  • Bård Sundrehagen

    Executive Vice President of Business Development

    • Tenure: 1.3yrs
  • Njaal Kind

    Chief Financial Officer

    • Tenure: 0yrs
  • Hilja Ibert

    Chief Executive Officer

    • Tenure: 1.3yrs

Board Members

  • Espen Jørgensen (44yo)

    Director

    • Tenure: 0yrs
  • Tomas Settevik (59yo)

    Chairman

    • Tenure: 0yrs
  • Ingrid Akay

    Director

    • Tenure: 0yrs
  • Bendik Sundrehagen

    Director

    • Tenure: 0yrs
  • Kari Krogstad

    Director

    • Tenure: 0yrs
  • Henrik Krefting

    Director

    • Tenure: 0.4yrs
  • Susanne Stuffers

    Director

    • Tenure: 0.4yrs

Company Information

Gentian Diagnostics AS's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Gentian Diagnostics AS
  • Ticker: GENT-ME
  • Exchange: OB
  • Founded: 2001
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: kr706.673m
  • Shares outstanding: 15.40m
  • Website: https://www.gentian.com

Number of Employees


Location

  • Gentian Diagnostics AS
  • Bjornasveien 5
  • Moss
  • Østfold
  • 1596
  • Norway

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GENT-MEOB (Oslo Bors)YesShare CapitalNONOKDec 2016

Biography

Gentian Diagnostics AS researches, develops, and produces biochemical reagents for use in medical diagnostics and research. It offers in-vitro diagnostic (IVD) and molecular diagnostic tests for medical la ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 21:54
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.